CN105833184B - A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application - Google Patents
A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application Download PDFInfo
- Publication number
- CN105833184B CN105833184B CN201610302578.1A CN201610302578A CN105833184B CN 105833184 B CN105833184 B CN 105833184B CN 201610302578 A CN201610302578 A CN 201610302578A CN 105833184 B CN105833184 B CN 105833184B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medical fluid
- medicine composition
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 238000000855 fermentation Methods 0.000 title claims abstract description 48
- 230000004151 fermentation Effects 0.000 title claims abstract description 48
- 239000012530 fluid Substances 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 230000000302 ischemic effect Effects 0.000 claims abstract description 19
- 241000411851 herbal medicine Species 0.000 claims abstract description 18
- 230000006907 apoptotic process Effects 0.000 claims abstract description 14
- 230000036542 oxidative stress Effects 0.000 claims abstract description 13
- 208000018152 Cerebral disease Diseases 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 12
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 12
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 12
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 12
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 12
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 12
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 12
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 12
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 12
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 12
- 239000009636 Huang Qi Substances 0.000 claims abstract description 12
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 11
- 241000168720 Panax japonicus Species 0.000 claims abstract description 11
- 235000003174 Panax japonicus Nutrition 0.000 claims abstract description 11
- 244000143590 Salvia chinensis Species 0.000 claims abstract description 11
- 235000007154 Salvia chinensis Nutrition 0.000 claims abstract description 11
- 241000589220 Acetobacter Species 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 9
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 9
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 9
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 9
- 235000013976 turmeric Nutrition 0.000 claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 208000002173 dizziness Diseases 0.000 claims description 11
- 206010019233 Headaches Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 231100000869 headache Toxicity 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 239000002893 slag Substances 0.000 claims description 5
- 208000009205 Tinnitus Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 231100000886 tinnitus Toxicity 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 244000170916 Paeonia officinalis Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 69
- 230000000694 effects Effects 0.000 abstract description 48
- 230000006698 induction Effects 0.000 abstract description 27
- 210000004556 brain Anatomy 0.000 abstract description 17
- 230000006378 damage Effects 0.000 abstract description 14
- 210000002889 endothelial cell Anatomy 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 10
- 210000004088 microvessel Anatomy 0.000 abstract description 10
- 230000032683 aging Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 4
- 238000007792 addition Methods 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 17
- 102000019197 Superoxide Dismutase Human genes 0.000 description 14
- 108010012715 Superoxide dismutase Proteins 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 229960003180 glutathione Drugs 0.000 description 12
- 210000003414 extremity Anatomy 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 241001092040 Crataegus Species 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 241000723353 Chrysanthemum Species 0.000 description 8
- 230000001914 calming effect Effects 0.000 description 8
- 208000034783 hypoesthesia Diseases 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 231100000862 numbness Toxicity 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000003698 anagen phase Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010019468 Hemiplegia Diseases 0.000 description 5
- 102000017946 PGC-1 Human genes 0.000 description 5
- 108700038399 PGC-1 Proteins 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000035861 hematochezia Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 206010027339 Menstruation irregular Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 201000007201 aphasia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000032677 cell aging Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 description 2
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 102000000344 Sirtuin 1 Human genes 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 208000012866 low blood pressure Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- -1 oxygen radical Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 239000002372 hematologic agent Substances 0.000 description 1
- 229940124562 hematologic agent Drugs 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition, the fermentation medical fluid of its preparation and preparation method and applications, the Chinese medicine composition includes following raw material by weight: 160-480 parts of pueraria lobata, 80-320 parts of Radix Salviae Miltiorrhizae, 120-400 parts of Radix Paeoniae Alba, 120-400 parts of Radix Astragali, 40-240 parts of turmeric, 60-280 parts of Rhizoma Atractylodis Macrocephalae, 40-240 parts of semen brassicae, 60-280 parts of hawthorn, 60-280 parts of radix bupleuri, 60-280 parts of chrysanthemum, 40-240 parts of Rhizoma Gastrodiae, 60-280 parts of panax japonicus, 60-280 parts of rhizoma cyperi, 40-240 parts of salvia chinensis.Every 10-50 parts of 10000 parts of additions saccharomycete, 10-50 parts of acetobacter, 10-50 parts of Bacillus acidi lactici in the fermentation medical fluid, remaining is decocting for Chinese herbal medicine liquid, carries out fermentation and is made.Experiment shows that the fermentation medical fluid is obvious to brain microvessel endothelial cells in vitro oxidativestress damage effect, can significantly inhibit brain microvessel endothelial cells in vitro apoptosis and the aging of hydrogen peroxide induction.Clinical test shows that Chinese medicine composition fermentation medical fluid can effectively treat ischemic cerebral disease, and treatment safety is effective, has no adverse effects to patient's hepatic and renal function, can take for a long time, is worth clinical application.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, specially a kind of Chinese medicine composition, the fermentation medical fluid of its preparation and preparation side
Method and application, are particularly suitable for the treatment of ischemic cerebral disease.
Background technique
Ischemic cerebral disease (ischemic encephalopathy): refer to due to low blood pressure, sudden cardiac arrest, blood loss, asphyxia
Etc. cerebral injury caused by reasons.In clinic after cerebral ischemia caused encephalopathy include cerebral arterial thrombosis, vascular dementia, headache,
Dizziness, depression, tinnitus and insomnia etc. have the characteristics of high incidence, high disability rate, high mortality.Lead to human death
One of three big principal diseases, are only second to heart disease and cancer.
The main reason for causing ischemic cerebral disease has: the 1. inside and outside arteriarctia of cranium or occlusion；2. cerebral embolism；3. blood
Pipe lesion；4. Hemodynamic Factors；5. hematologic agent etc..It is anti-that a series of cascades are generated in ischemic cerebral disease development process
It should include energy decline, calcium balance disorder, response to oxidative stress, the activation of phosphatidase, arachidonic release etc..It is right at present
The research of Mechanism of Cerebral Ischemic Injury is concentrated mainly on the damage of oxygen radical, excitatory amino acid, intracellular calcium overload, mitochondria
Wound, inflammatory reaction and Apoptosis etc..
Modern surgical treatment Ischemic Encephalopathy mainly utilizes the neuron of Penumbra zone to be resistant to the time (therapeutic window) of ischemic, uses
Various methods restore brain blood flow, save dying nerve cell, conservative therapy is then based on thrombolysis.Although developing currently on the market
Go out some therapeutic agents, however since ischemic cerebral disease has diversity and complexity, though these drugs show in the treatment
Certain curative effect, but be all acted on by single mechanisms play, there is always certain deficiencies.
Summary of the invention
It is an object of the invention to provide a kind of Chinese medicine composition, the fermentation medical fluid of its preparation and preparation method and applications, overcome
The prior art is insufficient, significant in efficacy, safe and reliable and economical and practical, can be effectively reduced the disease incidence of ischemic cerebral disease and dead
Rate is died, is improved the quality of living.
In order to solve the above technical problems, the technical scheme adopted by the invention is that: a kind of Chinese medicine composition, including by weight
The following raw material of part meter: 160-480 parts of pueraria lobata, 80-320 parts of Radix Salviae Miltiorrhizae, 120-400 parts of Radix Paeoniae Alba, 120-400 parts of Radix Astragali, turmeric 40-
240 parts, 60-280 parts of Rhizoma Atractylodis Macrocephalae, 40-240 parts of semen brassicae, 60-280 parts of hawthorn, 60-280 parts of radix bupleuri, 60-280 parts of chrysanthemum, Rhizoma Gastrodiae
40-240 parts, 60-280 parts of panax japonicus, 60-280 parts of rhizoma cyperi, 40-240 parts of salvia chinensis.
In preferred scheme, observation of curative effect is treated according to giving consideration to both the incidental and fundamental principle combination clinical syndrome differentiation, the Chinese medicine composition
Raw material are as follows: 320 parts of pueraria lobata, 160 parts of Radix Salviae Miltiorrhizae, 240 parts of Radix Paeoniae Alba, 240 parts of Radix Astragali, 80 parts of turmeric, 120 parts of Rhizoma Atractylodis Macrocephalae, semen brassicae 80
Part, 120 parts of hawthorn, 120 parts of radix bupleuri, 120 parts of chrysanthemum, 80 parts of Rhizoma Gastrodiae, 120 parts of panax japonicus, 120 parts of rhizoma cyperi, 80 parts of salvia chinensis.
The invention further relates to the preparation methods of the Chinese medicine composition, i.e., will weigh Chinese medicine material according to the ratio, are added former
The water of 8-10 times of total weight of material, first intense fire are heated to boiling and are cooked by slow fire 30-60min again, decoct to 4-5 times of water, remove slag
Filter obtains the decocting for Chinese herbal medicine liquid of the Chinese medicine composition.
Further, the Chinese medicine material after adding water first impregnates 20-60min, then carries out heating decoction.
The invention further relates to a kind of fermentation medical fluids of Chinese medicine composition, by weight: containing in every 10000 parts of fermentations medical fluid
There are 10-50 parts of saccharomycete, 10-50 parts of acetobacter, 10-50 parts of Bacillus acidi lactici, remaining is decocted for the Chinese medicine of Chinese medicine composition preparation
Boil liquid.
In preferred scheme, observation of curative effect is treated according to giving consideration to both the incidental and fundamental principle combination clinical syndrome differentiation, the Chinese medicine composition
Ferment medical fluid, by weight: containing 10 parts of saccharomycete, 10 parts of acetobacter, Bacillus acidi lactici 10 in every 10000 parts of fermentations medical fluid
Part, remaining is the decocting for Chinese herbal medicine liquid of Chinese medicine composition preparation.
The invention further relates to the methods of the fermentation medical fluid, and the specific steps are take saccharomycete, acetobacter and cream according to the ratio
After acidfast bacilli, decocting for Chinese herbal medicine liquid is added, ferments 10-20 days at 22-37 DEG C, filter, fermentation medical fluid finished product can be obtained in disinfection.
The invention further relates to the fermentation medical fluids of the Chinese medicine composition or Chinese medicine composition to treat ischemic brain in preparation
Application in terms of medicine.
The invention further relates to the fermentation medical fluids of the Chinese medicine composition or Chinese medicine composition to treat oxidative stress in preparation
Application in terms of caused apoptosis of vascular endothelial cell drug
The invention further relates to the fermentation medical fluid of the Chinese medicine composition or Chinese medicine composition prepare treatment vascular dementia,
Application in terms of the drugs such as headache, dizziness, tinnitus.
Further, the invention further relates to the fermentation medical fluids of the Chinese medicine composition or Chinese medicine composition treats oxygen in preparation
Change stress caused by application in terms of Injury of Cerebral Microvascular Endothelial Cells drug.
Further, the present invention can also play a role in terms for the treatment of clinical ischemic cerebrovascular disease.
Herbal pharmacology mechanism of the invention:
Pueraria lobata: it is sweet, it is pungent, it is cool.Returns spleen, stomach meridian.Expelling pathogenic factors from muscles and skin is brought down a fever, and promoting eruption promotes the production of body fluid to quench thirst, Shengyang Zhixie.Cure mainly fever caused by exogenous pathogens
Headache, hypertension neck pain, it is thirsty, quench one's thirst, measles without adequate eruption, hot dysentery, diarrhea.Its main component Pueraria Flavonid and Puerarin
Platelet aggregation can be reduced, blood vessel is expanded, improves microcirculation, vascular resistence is reduced, increases blood flow, and then improves cerebral ischemia
State, the cranial vascular diseases such as prevention and treatment cerebral infarction, hemiplegia.
Radix Salviae Miltiorrhizae: it is bitter, it is slightly cold.Enter the heart, Liver Channel.Promoting blood circulation, inducing meastruation to relieve menalgia, relieving restlessness and restlessness, cool blood to disappear carbuncle.Cure mainly head, chest
The side of body, abdomen pain due to blood stasis, accumulation, irregular menstruation, dysmenorrhea menostasis, postpartum stasis abdominal pain, arthralgia are beaten the stasis of blood swell, the warm disease heart
It is tired, palpitation due to deficiency of blood, sore swollen toxin, red rash scabies.Radix Salviae Miltiorrhizae can antithrombus formation, inhibit platelet aggregation, while expanding peripheral blood
Pipe increases cerebral blood flow (CBF), improves microcirculation.
Radix Paeoniae Alba: cool, bitter acid, it is slightly cold.Enter liver, the spleen channel.Replenishing blood and soft liver, calming the liver and relieving pain.Cure mainly chest and abdomen pain over the hypochondriac region, dysentery
Abdominal pain, spontaneous sweating, fever due to yin deficiency.Its main component Paeoniflorin can antithrombotic and platelet aggregation, while can spasmolysis, analgesia,
There is protection and maintenance effect well to human body cardiovascular and cerebrovascular.
Radix Astragali: sweet, tepor.Return lung, spleen, liver and kidney channel.Invigorating qi for consolidating superficies, arrest sweating admittedly take off, torr sore myogenic, inducing diuresis for removing edema.It cures mainly
Deficiency of vital energy and acking in strength, the sinking of qi of middle-jiao, rush down prolapse of the anus for a long time, uterine bleeding of having blood in stool, exterior deficiency spontaneous perspiration, ulcer is difficult to burst, burst for a long time and does not holds back, blood deficiency chlorosis, interior heat
It quenches one's thirst, chronic nephritis, albuminuria, diabetes.Radix Astragali has antioxidation, and main component astragalus flavonid can increase SOD
Activity reduces damage of the lipid peroxide to biomembrane.In addition, the expansible peripheral blood vessel of Radix Astragali, reduces peripheral resistance, protection
The cerebrovascular.
Turmeric: pungent, bitter, temperature.Returns spleen, Liver Channel.Breaking blood and promoting the circulation of qi, it is inducing meastruation to relieve menalgia.It cures mainly chest side of body to twinge, amenorrhoea , wei lump in the abdomen, rheumatism
Shoulder arm pain, tumbling and swelling.Curcumin has anti-oxidant, analgesic activity, may also suppress platelet aggregation, reduces blood viscosity,
Antithrombus formation.
Rhizoma Atractylodis Macrocephalae: bitter, sweet, warm.Returns spleen, stomach meridian.Strengthening the spleen and replenishing qi, eliminate dampness and have diuretic effect, hidroschesis, miscarriage prevention.Cure mainly spleen eating less, abdominal distension
Diarrhea, phlegm retention anti-dazzle nervous, oedema, spontaneous perspiration, threatened abortion.Rhizoma Atractylodis Macrocephalae can obviously inhibit platelet aggregation, expand blood vessel.
Semen brassicae: pungent, warm.It attaches to the lung and stomach meridians.Warm lung slit phlegm benefit gas, dissipating bind are removed obstruction in channels to relieve pain.Cure mainly cough and phlegm；The fullness sensation in chest side of body
Bitterly；Extremity numbness；Painful swelling of joints；Multiple abscess with damp phlegm；Negative subcutaneous ulcer pyogenic infections.Control acute mastitis, breast cancer, mammary gland pain, tuberculosis, phlegm retention cough and asthma, chest
Turgor pain is coerced, gastric disorder causing nausea vomiting, aphasia from apoplexy, limbs numbness pain is numb, tinea pedis, negative subcutaneous ulcer, pyogenic infections, treating swelling and pain by traumatic injury.It can treat in
Wind-induced extremity numbness, the sequelae such as dysphasia.
Hawthorn: tepor, it is sour sweet.Returns spleen, stomach, Liver Channel.Food digesting stomach fortifying activates blood circulation and disperses blood clots, convergence and dysentery.It cures mainly carnivorous stagnant
Product, a lump in the abdomen causing distension and pain, abdominal distension feeling of fullness, stasis blocking abdominal pain, phlegm retention, diarrhea, discharging fresh blood stool etc..The accessible local extravasated blood state of hawthorn, drop
Low blood pressure and cholesterol, softening blood vessel, while flavonoids contained by hawthorn and vitamin C, carrotene can be blocked and be reduced certainly
It is generated by base, anti-oxidant and anti-aging.
Radix bupleuri: slightly cold, bitter, pungent.Return liver warp, gallbladder channel.Saturating table expels the heat-evil, soothing liver-qi stagnation.It is past to cure mainly cold, fever, fever and chills
Come, malaria, liver depression and qi stagnation, chest and rib distending pain, rectal prolapse, uterus fall off, irregular menstruation.Nerve center is adjusted in saikoside, adjusts
Relieving mood, and there is anti-inflammatory, strengthen immunity effect.
Chrysanthemum: sweet, slightly cold.Return lung, Liver Channel.Dispelling wind and heat from the body, calming the liver and improving eyesight, the cough that disappears analgesic.It is swollen to cure mainly headache and dizziness, hot eyes
Bitterly, the illnesss significant effect such as anemopyretic cold, cough also has effects that refresh the mind.Chrysanthemum can reduce glutathione peroxidating,
There is obvious protective function to the ultra-oxygen anion free radical damage of biomembrane, while the penetrating of mouse capillary can also be influenced
Property, increase capillary resistance, to have anti-inflammatory effect.
Rhizoma Gastrodiae: sweet, flat.Return liver warp.Inflammation Zhijing, suppressing liver-YANG, dispelling wind and removing obstruction in the meridians.Gastrodin can treat cerebrovascular disease head
Bitterly, and increase periphery and coronary blood flow, protect cardiovascular and cerebrovascular.In addition, for facial nerve tics caused by apoplexy, limb
The sequelae such as body numbness, hemiplegia, failure of memory also have improvement result.
Rhizoma cyperi: slight bitter sweet and neutral.Enter liver, tri-jiao channel.Regulating the flow of vital energy and dispeling melancholy, menstruction regulating and pain relieving.Chest, the side of body, abdominal distention are cured mainly, is digested
It is bad, irregular menstruation, amenorrhea and algomenorrhea, cold hernia stomachache, swollen breasts.Rhizoma cyperi total alkaloid, glucoside, flavonoids and phenolic compound
Aqueous solution have apparent antihypertensive effect and anti-inflammatory effect, inflammation when can reduce peripheral blood resistance and cerebral ischemia re-pouring is anti-
It answers.
Panax japonicus: sweet, slight bitter, temperature.Enter liver, tri-jiao channel.Dispelling wind and heat from the body, calming the liver and improving eyesight.It cures mainly weak after illness；Appetite is not
Vibration；Cough due to consumptive disease；Hemoptysis；It spits blood；Bleeding from five sense organs or subcutaneous tissue；Hematochezia hematuria；Vicarious menstruation；Metrorrhagia and metrostaxis；Traumatic hemorrhage；Abdominal mass；Blood stasis closed；Postpartum stasis of blood yin
Abdominal pain；Traumatic injury；Rheumatic arthritis；Carbuncle swells；Hemorrhoid；Venomous snake bite.Panax japonicus total saponin have stronger removing super oxygen yin from
Sub- Free Radical and anti-inflammatory effect can protect cardiovascular and cerebrovascular, antitumor and anti-aging.
Salvia chinensis: also known as Salvia chinensis, it trembles with fear, bitter.Enter liver, gallbladder channel.Activating microcirculation and removing stasis medicinal, clearing heat and promoting diuresis, mass dissipating and swelling eliminating.The main moon
Through uncomfortable；Dysmenorrhea；Menostasis；Metrorrhagia and metrostaxis, hematochezia；Jaundice with damp-heat pathogen；Hot toxic-heat and blood stasis；Leaching pain；Leukorrhagia；Treating rheumatic ostealgia；Scrofula；Sore swells；
Acute mastitis；Shingles zoster；Leprosy；Bruise wound is swollen.Its extract root of red-rooted salvia phenolic acid B can reduce the inflammatory reaction of rats after cerebral ischemic reperfusion
With the Apoptosis of ischemic tissue of brain.
Beneficial effects of the present invention:
Traditional Chinese medicine thinks that the basic pathogenesis of ischemic cerebral disease is imbalance of yin and yang, and qi and blood is inverse disorderly, and with the deficiency of liver-yin and kidney-yin, qi and blood declines few
For void；It is real with wind, fire, phlegm, gas, the stasis of blood, therefore the present invention uses calming the liver to stop the wind, dissipating phlegm for resuscitation, removing heat by catharsis expells the pathogenic heat, nourishing the liver and kidney,
Nourishing qi and blood therapy cube.Wherein pueraria lobata inducing diaphoresis is brought down a fever cool blood, and rising Yang can enter brain dredging collateral, and Radix Astragali QI invigorating is slitted with handsome blood, semen brassicae
Phlegm is had one's ideas straightened out, Radix Paeoniae Alba enriching yin analgesic, hawthorn blood circulation stagnation resolvation, Rhizoma Atractylodis Macrocephalae strengthening the spleen and replenishing qi, Rhizoma Gastrodiae is calming the liver to stop the wind qi-restoratives, and the saturating table of radix bupleuri is let out
Heat, soothing liver-qi stagnation, lifting disease, chrysanthemum dispelling wind and heat from the body, calming the liver and improving eyesight, Radix Salviae Miltiorrhizae promoting blood circulation is inducing meastruation to relieve menalgia, and salvia chinensis menstruation regulating is living
Blood, rhizoma cyperi regulating the flow of vital energy and dispeling melancholy is inducing meastruation to relieve menalgia, panax japonicus strengthening by means of tonics, removing blood stasis and acesodyne, eliminating the phlegm of stopping blooding.Make a general survey of full side, all medicines share,
It being capable of calming the liver to stop the wind, eliminating thrombus and removing obstruction in channels, inhibition thrombosis, the effect for preventing and treating ischemic cerebral disease.With the Chinese medicine of existing open invention
Composition and fermentation medical fluid are compared, and Chinese medicine material of the invention is simple and easy to get, and fermentation medical fluid preparation method is simple, quick, are had
Prescription science, dialectical prescribe medicine, the advantages that mechanism is apparent, safe and efficient.And by experiment and clinical observation verifying, the fermentation medical fluid
Have the function of calming the liver to stop the wind, eliminating thrombus and removing obstruction in channels, inhibition thrombosis, the protection cerebrovascular, prevention and treatment ischemic cerebral disease.
Detailed description of the invention
Attached drawing 1 is various concentration H2O2Influence to BMECs proliferation activity, ordinate are ability of cell proliferation, with % table
Show.
Attached drawing 2 is influence of the fermentation medical fluid (hereinafter referred to as STL) of Chinese medicine composition to BMECs proliferation activity, and ordinate is
Ability of cell proliferation is indicated with %.
Attached drawing 3 is the present invention to H2O2The influence of the BMECs proliferation activity of induction, ordinate are ability of cell proliferation, use %
It indicates.
Attached drawing 4 is the present invention to H2O2The influence of the BMECs apoptosis situation of induction；Wherein A: normal group, B:H2O2(400μ
Mol/L) group, C:H2O2(400 μm of ol/L)+STL (0.025g/L) group, D:H2O2(400 μm of ol/L)+STL (0.05g/L) group, E:
H2O2(400 μm of ol/L)+STL (0.1g/L) group.
Attached drawing 5 is the present invention to H2O2The influence of the aging situation of the BMECs of induction；Wherein A: normal group, B:H2O2(400
μm ol/L) group, C:H2O2(400 μm of ol/L)+STL (0.025g/L) group, D:H2O2(400 μm of ol/L)+STL (0.05g/L) group,
E:H2O2(400 μm of ol/L)+STL (0.1g/L) group.
Attached drawing 6 is the present invention to H2O2The ROS activity influence of the BMECs of induction.Wherein A: normal group, B:H2O2(400μ
Mol/L) group, C:STL (0.1g/L) group, D:H2O2(400 μm of ol/L)+STL (0.1g/L) group, E:H2O2(400μmol/L)+STL
(0.1g/L)+inhibitor group.
Attached drawing 7-8 is the present invention to H2O2The SOD activity influence of the BMECs of induction, the ordinate in Fig. 7 are mean fluorecence
Intensity.
Attached drawing 9 is the present invention to H2O2The GSH level of the BMECs of induction influences.
Attached drawing 10-11 is the present invention to H2O2The influence of the sirt1 protein expression level of the BMECs of induction；1 in Figure 10: just
Normal group, 2:H2O2(400 μm of ol/L) group, 3:STL (0.1g/L) group, 4:H2O2(400 μm of ol/L)+STL (0.1g/L) group, 5:STL
(0.1g/L)+inhibitor group, 6:H2O2(400 μm of ol/L)+STL (0.1g/L)+inhibitor group.
Attached drawing 12-13 is the present invention to H2O2The influence of the p21 protein expression level of the BMECs of induction, Tu12Zhong, 1: just
Normal group, 2:H2O2(400 μm of ol/L) group, 3:STL (0.1g/L) group, 4:H2O2(400 μm of ol/L)+STL (0.1g/L) group, 5:STL
(0.1g/L)+inhibitor group, 6:H2O2(400 μm of ol/L)+STL (0.1g/L)+inhibitor group.
Attached drawing 14-15 is the present invention to H2O2The influence of the PGC-1 α protein expression level of the BMECs of induction；1 in Figure 14:
Normal group, 2:H2O2(400 μm of ol/L) group, 3:STL (0.1g/L) group, 4:H2O2(400 μm of ol/L)+STL (0.1g/L) group, 5:
STL (0.1g/L)+inhibitor group, 6:H2O2(400 μm of ol/L)+STL (0.1g/L)+inhibitor group.
Specific embodiment
Below with reference to specific implementation and table, the present invention is furture elucidated.These embodiments are interpreted as being merely to illustrate
The present invention rather than for limiting the scope of the invention.After having read the content of the invention recorded, art technology
Personnel can make various changes or modifications the present invention, these equivalence changes and modification equally fall into claims of the present invention institute
The range of restriction.
Embodiment 1: a kind of Chinese medicine composition fermentation medical fluid and preparation method thereof, every 10000 parts of fermentations medical fluid is by saccharomycete
10 parts, 10 parts of acetobacter, 10 parts of Bacillus acidi lactici are added decocting for Chinese herbal medicine liquid, and ferment 15 days in 22 DEG C, filter, and Pasteur disappears
Poison packaging is canned to obtain fermentation medical fluid finished product.Decocting for Chinese herbal medicine liquid is made of following raw material: 160 parts of pueraria lobata, 80 parts of Radix Salviae Miltiorrhizae, Radix Paeoniae Alba
120 parts, 120 parts of Radix Astragali, 40 parts of turmeric, 60 parts of Rhizoma Atractylodis Macrocephalae, 40 parts of semen brassicae, 60 parts of hawthorn, 60 parts of radix bupleuri, 60 parts of chrysanthemum, Rhizoma Gastrodiae
40 parts, 60 parts of panax japonicus, 60 parts of rhizoma cyperi, 40 parts of salvia chinensis.The preparation method of decoction liquor is: by weight by various Chinese medicines and water
It for 1:10, impregnates Chinese medicine 20 minutes, intense fire is heated to boiling and is cooked by slow fire again 60 minutes, decocts to 5 times of waters, slag filtration obtains
To decocting for Chinese herbal medicine liquid.
Embodiment 2: a kind of Chinese medicine composition fermentation medical fluid and preparation method thereof, every 10000 parts of fermentations medical fluid is by saccharomycete
40 parts, 40 parts of acetobacter, 40 parts of Bacillus acidi lactici are added decocting for Chinese herbal medicine liquid, and ferment 10 days in 30 DEG C, filter, and Pasteur disappears
Poison packaging is canned to obtain fermentation medical fluid finished product.Decocting for Chinese herbal medicine liquid is made of following raw material: 160 parts of pueraria lobata, 320 parts of Radix Salviae Miltiorrhizae, Radix Paeoniae Alba
240 parts, 120 parts of Radix Astragali, 80 parts of turmeric, 240 parts of Rhizoma Atractylodis Macrocephalae, 80 parts of semen brassicae, 120 parts of hawthorn, 120 parts of radix bupleuri, 120 parts of chrysanthemum,
80 parts of Rhizoma Gastrodiae, 120 parts of panax japonicus, 80 parts of rhizoma cyperi, 120 parts of salvia chinensis.The preparation method of decoction liquor is: various Chinese medicines are pressed with water
Weight ratio is 1:8, is impregnated Chinese medicine 40 minutes, and intense fire is heated to boiling and is cooked by slow fire again 50 minutes, decocts to 5 times of waters, removes slag
Decocting for Chinese herbal medicine liquid is obtained by filtration.
Embodiment 3: a kind of Chinese medicine composition fermentation medical fluid and preparation method thereof, every 10000 parts of fermentations medical fluid is by saccharomycete
50 parts, 50 parts of acetobacter, 50 parts of Bacillus acidi lactici are added decocting for Chinese herbal medicine liquid, and ferment 20 days in 37 DEG C, filter, and Pasteur disappears
Poison packaging is canned to obtain fermentation medical fluid finished product.Decocting for Chinese herbal medicine liquid, it is made of following raw material: 480 parts of pueraria lobata, 320 parts of Radix Salviae Miltiorrhizae, white
400 parts of Chinese herbaceous peony, 400 parts of Radix Astragali, 240 parts of turmeric, 280 parts of Rhizoma Atractylodis Macrocephalae, 240 parts of semen brassicae, 280 parts of hawthorn, 280 parts of radix bupleuri, chrysanthemum 280
Part, 240 parts of Rhizoma Gastrodiae, 280 parts of panax japonicus, 280 parts of rhizoma cyperi, 240 parts of salvia chinensis.The preparation method of decoction liquor is: by various Chinese medicines
By weight it is 1:9 with water, impregnates Chinese medicine 60 minutes, intense fire is heated to boiling and is cooked by slow fire again 30 minutes, decocts to 4 times of water
Amount, slag filtration obtain decocting for Chinese herbal medicine liquid.
Above-mentioned herb fermenting medical fluid is respectively taken 1 time in the morning, afternoon and evening daily each taking 60mL.The suitable meal of the bad person of gastrointestinal system
After take.
The diagnostic criteria of cerebral arterial thrombosis: 1. primary symptom: hemiplegia, mind know faint, sluggish speech or body feels different in silence, partially
Often, dispute skew；2. minor symptom: headache, dizziness, the variation of pupil mind, drinking-water hair choke, mesh not wink, incoordination partially；3. Acute onset,
It is before the onset to have inducement more, often there is premonitory symptom；4. age of onset is mostly at 40 years old or more.
Have two minor symptoms of two primary symptoms or more or a primary symptom, it can be true in conjunction with onset, inducement, premonitory symptom, age
It examines；Do not have above-mentioned condition, can also be made a definite diagnosis in conjunction with imageological examination result.
Curative effect determinate standard: basic to restore: >=81%, 6 points or less；Marked improvement: 56%~80%；Progress: 36%~
55%；It is slightly progressive: 11%~35%；It is unchanged: < 11%；Deteriorate: (including death) negative value.
Substantive distinguishing features, validity and safety in order to better illustrate the present invention, below using quasi- ischemic injuries brain
Microvascular endothelial cells oxidativestress damage model, gives using Chinese materia medica preparation of the invention and handles, and observe therapeutic effect and
Potential mechanism.
For record and the statistical result convenience of mapping, following Chinese medicine composition fermentation medical fluid is indicated with STL.
Experimental method
1) cell culture: the Brain Microvascular Endothelial (BMEC) purchased from this letter Biotechnology Co., Ltd of Shanghai is used
DMEM high glucose medium containing 10% fetal calf serum, 1% mycillin contains 5%CO in 37 DEG C2Incubator in cultivate, every 2
It is changed the liquid once, and takes growth conditions stable and the cell in logarithmic phase is for testing.
2) cell model is established: the BMEC cell inoculation of logarithmic growth phase is in 96 orifice plates, after cell is adherent, inhales and abandons hole
The H of various concentration (50-800 μm of ol/L) is added by every 100 μ L of hole for interior liquid2O2, blank, which is normally organized, is only added culture medium, each
Concentration sets 6 multiple holes.Hydrogen peroxide stimulation is added 20 μ l MTT (5mg/mL) afterwards for 24 hours and continues to be incubated for 4h, abandons supernatant, and every hole is added
150 μ L DMSO dissolution, measures the light absorption value OD in each hole at enzyme-linked immunosorbent assay instrument 570nm570nm, determine 503nhibiting concentration
(IC50)。
3) experimental group: (1) normal group；(2)H2O2(400 μm of ol/L) handles group for 24 hours；(3) various concentration STL (1.25g/
L-40g/L 12h group) is handled；(4) after various concentration STL (0.0125g/L-0.4g/L) pre-processes 12h, liquid is discarded supernatant, then plus
Enter H2O2(400 μm of ol/L) handles group for 24 hours.With the light absorption value in mtt assay each hole of measurement at enzyme-linked immunosorbent assay instrument measurement 570nm
OD570nm。
4) experimentation:
1. DAPI is dyed: the BMEC cell inoculation of logarithmic growth phase sets 6 well culture plates in 6 orifice plates, every 1000 μ L of hole
In 37 DEG C, contain 5%CO2Incubator in cultivate.After cultivating 20h, if Normal group, H2O2(400 μm of ol/L) group, difference are dense
Spend STL (0.025g/L, 0.05g/L, 0.1g/L)+H2O2(400 μm of ol/L) group.Supernatant is abandoned after STL pretreatment 12h, is added
H2O2Continue culture for 24 hours.It inhales and abandons old culture solution, PBS is rinsed 5 minutes；4% paraformaldehyde room temperature fixes PBS rinsing 3 in 15 minutes
It is secondary, 10 minutes every time；DAPI working solution room temperature dyes 20 minutes；PBS is rinsed 3 times, every time 10 minutes；Fluorescence microscope is simultaneously
It takes pictures.
2. beta galactosidase dyes: the BMEC cell inoculation of logarithmic growth phase trains 6 holes in 6 orifice plates, every 1000 μ L of hole
Plate is supported in 37 DEG C, contains 5%CO2Incubator in cultivate.After cultivating 20h, if normal group, H2O2(400 μm of ol/L) group, difference are dense
Spend STL (0.025g/L, 0.05g/L, 0.1g/L) group+H2O2(400 μm of ol/L) group.Supernatant is abandoned after STL pretreatment 12h, is added
H2O2Continue culture for 24 hours.It inhales and abandons old culture solution, the PBS that 2mL is added in every hole is washed 3 times；1mL beta galactosidase dye is added in every hole
Dyeing fixer is sucked out in color fixing liquid, the fixed 15min of room temperature, and 2mLPBS washing is added three times in every hole, and each 3min is sucked out
1mL working solution is added in PBS, every hole, and 37 ° of overnight incubations, sealing six orifice plates with preservative film prevents from evaporating.Ordinary optical microscope
Lower observation is simultaneously taken pictures.
3. DCFH-DA probe loads: the BMECs of logarithmic growth phase is inoculated in 6 orifice plates, and every 1000 μ L of hole trains 6 holes
Plate is supported in 37 DEG C, contains 5%CO2Incubator in cultivate.After cultivating 20h, if normal group, H2O2(400 μm of ol/L) group, STL
(0.1g/L) group, STL (0.1g/L)+H2O2(400 μm of ol/L) group.Supernatant is abandoned after STL pretreatment 12h, adds H2O2Continue to train
It supports for 24 hours.Hydrogen peroxide stimulates 12h, handles cell according to ROS detection kit, fluorescence microscopy under the microscope, takes pictures, uses IPP6.0
Calculate average optical density.
4. SOD Activity determination: the cell inoculation of logarithmic growth phase is in 6 orifice plates, every hole addition 2mL, 12 hours in advance
Chinese medicine is added, after incubation, abandons supernatant, H is added2O2Processing 24 hours, cell is divided into normal group, H2O2(400μmol/mL)
Group, STL (0.1g/L) group, STL (0.1g/L)+H2O2(400 μm of ol/mL) group, sirt1 inhibitor group, Chinese medicine add hydrogen peroxide to add suppression
Preparation group.After effect 36 hours, after cell is cleaned 2 times with 4 DEG C of PBS, it is added after lysate and scrapes cell with cell scraper
It is put into the centrifuge tube of 1.5mL, cracks 30 minutes on ice, shaken 30 seconds every 5 minutes using vortex oscillator.4℃1000rpm
Supernatant is collected in centrifugation 10 minutes.It operates according to SOD kit reagent preparation, is detected with microplate reader.
5. GSH Activity determination: the cell inoculation of logarithmic growth phase is in 6 orifice plates, every hole addition 2mL, 12 hours in advance
Chinese medicine is added, after incubation, abandons culture solution and adds H2O2Processing 24 hours, cell is divided into normal group, H2O2(400μmol/
ML) group, STL (0.1g/L) group, STL (0.1g/L)+H2O2(400 μm of ol/mL) group, sirt1 inhibitor group, STL (0.1g/L)+
H2O2(400 μm of ol/mL)+inhibitor group.After effect 36 hours, after cell is cleaned 2 times with 4 DEG C of PBS, after lysate is added
Cell is scraped with cell scraper to be put into the centrifuge tube of 1.5mL, is cracked 30 minutes on ice, uses vortex oscillator every 5 minutes
Concussion 30 seconds.4 DEG C of 1000rpm are centrifuged 10 minutes, collect supernatant.It operates according to GSH kit reagent preparation, is examined with microplate reader
It surveys.
6. Western blot detects the protein expression of sirt1, p21 in BMECs: experiment group of cells culture will after terminating
Quantitative protein sample carries out electrophoresis and transferring film after 95 DEG C of denaturation 10min respectively, and then primary antibody is incubated for 4 DEG C of overnight and secondary antibody rooms
Temperature is incubated for 1h, last ECL substrate chemiluminescence colour developing.
5) index determining
Cell Proliferation vigor is detected according to mtt assay, DAPI decoration method detects Apoptosis situation, beta galactosidase dyeing
Method detects cell ageing situation, and DCFH-DA probe loads detection cell activity oxygen (ROS), SOD Activity determination, the inspection of GSH activity
It surveys, Western blot detects the protein expression of sirt1, P21 in BMECs.
6) statistical procedures
Experimental data using Sigma software analyze, Western blot data using Image J software analysis, data with
± s histogram graph representation uses one-way analysis of variance between group, is that difference has statistical significance with P < 0.05.
Experimental result
Wherein, Fig. 1 is various concentration H2O2Influence to BMECs proliferation activity, various concentration H2O2(50-800μmol/L)
Handle BMECs for 24 hours after, cell Proliferation vigor with concentration for the treatment of increase and decline (**P < 0.01), the results showed that H2O2It can be bright
Aobvious to inhibit BMECs proliferation activity, 503nhibiting concentration (IC50) is 400 μm of ol/L.
Fig. 2 is influence of the various concentration STL to BEMCs proliferation activity, at various concentration STL (0.0125g/L-0.4g/L)
Manage cell 12h after, cell Proliferation vigor with concentration for the treatment of increase and rise (##P<0.01).The result shows that: STL can obviously promote
Into cell viability.
Fig. 3 is the present invention to H2O2The influence of the BMECs proliferation activity of induction, compared with normal group；H2O2(400μmol/
L) group cell viability be decreased obviously (△△P<0.01)；With H2O2(400 μm of ol/L) group is compared, various concentration STL (0.05g/L-
0.2g/L)+H2O2(400 μm of ol/L) group cell viability obviously increase (▲▲P < 0.01).The result shows that: STL can be significantly inhibited
H2O2The BMECs vigor of induction declines.
Fig. 4 is the present invention to H2O2The influence of the BMECs apoptosis situation of induction, as shown in Figure 4, fluorescence microscopy is under the microscope
It was found that H2O2After (400 μm of ol/L) processing stimulates BMEC cell for 24 hours, karyopyknosis in the visual field, dyeing is deepened, and apoptosis occurs
Corpusculum or nuclear chromatin are gathered in nuclear membrane on one side in crescent, and notably karyorrhexis is at the corps ronds to differ in size.STL locates in advance
Reason group cellular morphology tends to be normal substantially and has dose dependent, rarely seen a small amount of core concentrating cells in high dose.The result shows that:
H2O2It can be obviously promoted Apoptosis, and the present invention can significantly inhibit H2O2The BMECs apoptosis of induction.
Fig. 5 is the present invention to H2O2The influence of the aging situation of the BMECs of induction, as shown in Figure 5, compared with normal group,
H2O2(400 μm of ol/L) processing stimulates in BMEC model group for 24 hours, and the activity of beta galactosidase is significant to be increased, and there is major part in the visual field
Cell is dyed blue deeply, shows model foundation success.With H2O2(400 μm of ol/L) group compares, beta galactosidase activity with
The increase of STL dosage gradually weaken, cellular colours are dyed to glaucous cell and significantly reduce close to normal, STL high dose
Cellular morphology tends to normal substantially in pretreated group.The result shows that: H2O2It can be obviously promoted cell ageing, and the present invention can be significant
Inhibit H2O2The BMECs aging of induction.
Fig. 6 and Fig. 7 is the present invention to H2O2The ROS activity influence of the BMECs of induction, by Fig. 6 and Fig. 7 it is found that with normal group
Compare, H2O2(400 μm of ol/L) group intracellular ROS level significantly increase (**P<0.01).With H2O2(400 μm of ol/L) group is compared,
STL(0.1g/L)+H2O2The significant decrease of (400 μm of ol/L) group intracellular ROS level (##P<0.01).With STL (0.1g/L)+H2O2
(400 μm of ol/L) group compares, be added sirt1 inhibitor group intracellular ROS obviously increase (▲▲P < 0.01).The result shows that: this
Invention can significantly inhibit H2O2The intracellular ROS of induction is generated and oxidativestress damage.
Fig. 8 is the present invention to H2O2The SOD activity influence of the BMECs of induction, as shown in Figure 8, compared with normal group, H2O2
(400 μm of ol/L) organize intracellular SOD level be remarkably decreased (**P<0.01).With H2O2(400 μm of ol/L) group is compared, STL (0.1g/
L)+H2O2The horizontal significantly raising of the intracellular SOD of (400 μm of ol/L) group (##P<0.01).With STL (0.1g/L)+H2O2(400μ
Mol/L) group compares, be added sirt1 inhibitor group intracellular SOD be substantially reduced (▲▲P < 0.01).The result shows that: the present invention
H can be dramatically increased2O2The intracellular SOD of induction generates and inhibits oxidativestress damage, protects brain microvessel endothelial cells in vitro.
Fig. 9 is the present invention to H2O2The GSH level of the BMECs of induction influences, as shown in Figure 9, compared with normal group, H2O2
(400 μm of ol/L) organize intracellular GSH level be remarkably decreased (**P<0.01).With H2O2(400 μm of ol/L) group is compared, STL (0.1g/
L)+H2O2The horizontal significantly raising of the intracellular GSH of (400 μm of ol/L) group (##P<0.01).With STL (0.1g/L)+H2O2(400μmol/
L) group compares, be added sirt1 inhibitor group intracellular GSH be substantially reduced (▲▲P < 0.01).The result shows that: the present invention can be shown
It writes and increases H2O2The intracellular GSH of induction generates and inhibits oxidativestress damage, protects brain microvessel endothelial cells in vitro.
Figure 10 and Figure 11 is the present invention to H2O2The influence of the sirt1 protein expression level of the BMECs of induction, by Figure 10 and
Figure 11 is it is found that compared with normal group, H2O2(400 μm of ol/L) group sirt1 protein expression be substantially reduced (**P < 0.01), STL
The apparent increase of (0.1g/L) group sirt1 protein expression (△P<0.05)；With H2O2(400 μm of ol/L) group compares, and STL (0.1g/L)+
H2O2The sirt1 protein expression of (400 μm of ol/L) group it is significantly raised (##P<0.01)；Compared with STL (0.1g/L) group, STL
The sirt1 protein expression of (0.1g/L)+inhibitor group be substantially reduced (▽▽P<0.01)；With STL (0.1g/L)+H2O2(400μmol/
L) group compares, STL (0.1g/L)+H2O2The sirt1 protein expression of (400 μm of ol/L)+inhibitor group be substantially reduced (▲▲P<
0.01).The result shows that: the present invention can inhibit oxidativestress damage, protect brain microvessel endothelial cells in vitro, and this effect with
Sirt1 signal path is related.
Figure 12 and Figure 13 is the present invention to H2O2The influence of the p21 protein expression level of the BMECs of induction, by Figure 12 and figure
13 it is found that compared with normal group, H2O2The p21 protein expression of (400 μm of ol/L) group it is significantly raised (**P < 0.01), STL (0.1g/
L) group p21 protein expression be substantially reduced (△P<0.05)；With H2O2(400 μm of ol/L) group compares, STL (0.1g/L)+H2O2(400μ
Mol/L) organize p21 protein expression be substantially reduced (##P<0.01)；Compared with STL (0.1g/L) group, STL (0.1g/L)+inhibitor
The p21 protein expression of group it is significantly raised (▽▽P<0.01)；With STL (0.1g/L)+H2O2(400 μm of ol/L) group compares, STL
(0.1g/L)+H2O2The p21 protein expression of (400 μm of ol/L)+inhibitor group it is significantly raised (▲▲P<0.01).The result shows that: this hair
It is bright to inhibit oxidativestress damage, brain microvessel endothelial cells in vitro is protected, and this effect is related with p21 signal path.
Figure 14 and Figure 15 is the present invention to H2O2The influence of the PCG-1 α protein expression level of the BMECs of induction, by Figure 14 and
Figure 15 is it is found that compared with normal group, H2O2(400 μm of ol/L) group PCG1- α protein expression be substantially reduced (**P < 0.01), STL
The apparent increase of (0.1g/L) group PCG-1 α protein expression (△P<0.05)；With H2O2(400 μm of ol/L) group compares, and STL (0.1g/L)+
H2O2The PCG-1 α protein expression of (400 μm of ol/L) group it is significantly raised (##P<0.01)；Compared with STL (0.1g/L) group, STL
The PCG-1 α protein expression of (0.1g/L)+inhibitor group be substantially reduced (▽▽P<0.01)；With STL (0.1g/L)+H2O2(400μ
Mol/L) group compares, STL (0.1g/L)+H2O2The PCG-1 α protein expression of (400 μm of ol/L)+inhibitor group be substantially reduced (▲▲P<
0.01).The result shows that: the present invention can inhibit oxidativestress damage, protect brain microvessel endothelial cells in vitro, and this effect with
PGC-1 alpha signal access is related.
Experiment conclusion
The cell Proliferation vigor of the brain microvessel endothelial cells in vitro of discovery enhancing hydrogen peroxide induction through the invention, inhibits cell
Aging, apoptosis；ROS activity is reduced, SOD, GSH activity are improved；Sirt1, PGC-1 α protein expression are improved, p21 albumen table is reduced
It reaches.Oxidative stress easily causes the apoptosis of cell, aging equivalent damage.PCG-1 α is emerging pass to be played in anti-oxidation stress system
The transcription regulaton factor of key effect, when oxidative stress, PGC-1 alpha active increases adjustable cell effect, it can induce antioxygen
Change enzyme such as glutathione peroxidase (GSH-PX), the expression of superoxide dismutase (SOD) improves tissue oxidation resistance.
The base of proteasome degradation PGC-1 α and the antioxidases such as sustained activation GSH, SOD is prevented after sirt1 deacetylation PGC-1 α
Because of expression, and then the generation of free radical is reduced, reaches oxidation resistant purpose.Therefore the present invention can be logical by activation sirt1 signal
Road regulates and controls PGC-1 α anti-oxidation stress, protects the cerebrovascular, prevents and treats ischemic cerebrovascular disease.In addition, what oxidative stress will lead to
DNA damage can raise the activity of aging gene p21, cause aging.Therefore the present invention can be by lowering p21 expression inhibiting blood vessel endothelium
The aging of cell prevents and treats ischemic cerebral disease in turn.
Clinical test embodiment
Based on above-mentioned experimental result, i.e. the traditional chinese medicine composition of the invention fermentation liquid medicine applying brain microvessel endothelial cells in vitro oxidation is answered
It is obvious to swash damage effect；Brain microvessel endothelial cells in vitro apoptosis and the aging of hydrogen peroxide induction can be significantly inhibited.In informed consent
In the case where and human treatment on the basis of, test treatment effect of the invention in chronic cerebral ischemia patient in clinical application
Fruit.
General information
In January, 2013 is chosen into SanXia University's hospital of traditional Chinese hospital's outpatient service during in January, 2016 and the acute ischemic being hospitalized
Wind patient 80, wherein male 39, women 41, the age 30~80 years old；The course of disease is 3d-60d, is randomly divided into treatment group 40
Example, control group 40.The neurological functional deficit scale for treating preceding two groups of patients is compared, two groups of clinical data differences
Not statistically significant (P > 0.05).
Diagnostic criteria
1. the cerebral thrombosis diagnostic criteria that Western medicine diagnostic criteria is revised according to nineteen ninety-five whole nation cerebrovascular disease academic conference
(classification of the 4th national cerebrovascular disease meeting cerebrovascular disease disease and diagnostic criteria China neurosurgery magazine, 1997；13
(1): 2).
2. Chinese medical discrimination category apoplex involving the channels and collaterals, wind-heat hemostasis, numbness hinders passages through which vital energy circulates patient.Symptoms include hemiplegia, dispute skew, speech
Not smoothgoing puckery or in silence, hemianesthesia is dizzy, and dark tongue quality or dark red or have ecchymosis, moss thin yellow or Huang, veins string or string are thin, and know without mind
It is faint.And (Ministry of Health of the People's Republic of China formulates new Chinese medicine clinic and grinds according to new Chinese medicine clinical observation guideline
Study carefully guideline first and collect .1993:32) determine observation case standard and observation index.
Treatment method
Treatment group's the traditional chinese medicine composition of the invention fermentation medical fluid for oral use, each 60ml take orally 3 times a day, and 30d is a treatment
Journey.Control group takes Xuesaitong dispersible tablet, and 2 tablets once (100mg), 3 times a day.Controlling for other cerebrovascular diseases is deactivated during observation
Treat drug.
Curative effect determinate standard
Using apoplexy scoring system, mind, language, motor function recovery degree are evaluated.Indices be divided into 5 grades (0~
4), total score is 28 points, artificial 0 point normal；Starting point point is minimum before treating is not less than 18 points；Efficacy evaluation method is treatment foreset
Point-post treatment integral)/post treatment integral × 100%；It is almost recovered >=85%；Effective >=50%；Effectively >=20%；In vain≤
20%.
Treatment results
Treatment group and control group clinical cure are respectively as follows: 15 (25%), and 7 (17.5%)；Effective is respectively 33
(82.5%) and 17 (42.5%)；It is effectively respectively 38 (95%), 30 (75%)；Invalid 2 (5%), 10
(25%).Two groups of obvious effective rate comparing differences have significance,statistical meaning (P < 0.01), show treatment group's curative effect better than control group.
In cure the desease time variation herb fermenting medical fluid of the present invention to patient's hemianesthesia, headache and dizzy and tongue nature, tongue fur
The improvement for time of curing the desease in is more apparent.
Table 1 is the variation of the pretherapy and post-treatment TCM syndrome for the treatment of group.
| TCM syndrome | Before treatment/example | After treatment/example | Disappearance rate/% |
| Hemiplegia, numbness | 25 | 11 | 56 |
| The strong language of tongue is not smoothgoing | 24 | 14 | 41.7 |
| Headache, dizzy, tinnitus | 32 | 12 | 62.5 |
| Tongue is red, yellow tongue fur | 33 | 16 | 51.5 |
Table 1
The comprehensive function score value for the treatment of group and control group is respectively 3.44 ± 0.61 Hes before the variation of comprehensive function is treated
3.57 ± 0.61, two groups are compared that there was no significant difference (P > 0.05)；It is respectively 1.49 ± 1.41 and 2.85 ± 1.57, two after treatment
Group, which compares, significant difference (P < 0.01), shows treatment group better than control group.
Typical case
Case 1
Huang, male, 58 years old, peasant, first visit on April 4 in 2013.Previously there are more than 10 years of history of hypertension, interruption medication tells 1
Feel right side extremity numbness before month from morning suddenly, does not give attention, aggravated in progressive with dizziness headache, in certain county hospital after 10d
Brain CT examination is shown: the left multiple infarct in brain basal ganglia region.Because being reluctant hospitalization, carrys out outpatient service then and see a doctor.See quarter: fat
Figure, mind is clear, and aphasia is had a dizzy spell, flushing, irritated, and right side limb adynamia, activity is difficult, diet can, stool is dry, small
Just normal, the dim red sublingual stasis of blood of tongue is stagnant, thick,yellow and greasy fur, wiry and rolling pulse.The traditional chinese medicine composition of the invention fermentation liquid medicine applying for oral use is given,
Each 60ml, takes orally 3 times a day, treats 30d.On May 5th, 2013 examines again, sees that patient includes extremity numbness, language problem, head
Most of symptom such as dizzy headache, coordination obstacle significantly improves, and while taking action be able to maintain good body steadiness with
Balance.
Case 2
Xiong, male, 77 years old, in first visit on October 12 in 2014.Main suit: being slow in action, and dull mind 3 months.Patient is in 2
It is unfavorable to suffer from right side limb activity after cerebral infarction before year, and decrease of memory and thinking is slow in reacting gradually aggravates, does not remember clearly
The age of oneself meets kith and kin and can not think address, goes out lost, and computing capability is decreased obviously, and used article can not find, and life is not
It can take care of oneself, examine as " vascular dementia ", through multiple diagnosis and treatment, effect is unobvious, seeks medical advice in inventor.See quarter: limbs on the right side of patient
Activity it is unfavorable, it is slow in reacting, can't take care of oneself, have a dull expression on one's face, dispute skew, memory, computing capability lose, receive can, sleep
Difference, pink tongue, yellow and greasy fur, wiry and rolling pulse.Give the traditional chinese medicine composition of the invention for oral use fermentation liquid medicine applying, each 60ml, daily 3
It is secondary oral, treat 20d.On November 2nd, 2014 examines again, sees that limbs of patient mobility is obviously improved, memory capability has improvement, energy
Recognize household and relative.Patient is advised to continue oral the traditional chinese medicine composition of the invention fermentation medical fluid March.Phone on March 10 returns within 2015
The patient is visited, patient's private prosecution limb activity ability fully recovers, and can remember and doctor's diagnosis and treatment process, and can remember oneself
The relevant informations such as name, age, self-care ability significantly increase.
Claims (7)
1. a kind of fermentation medical fluid of Chinese medicine composition, which is characterized in that by weight: containing in every 10000 parts of fermentations medical fluid
10-50 parts of saccharomycete, 10-50 parts of acetobacter, 10-50 parts of Bacillus acidi lactici, remaining is the decocting for Chinese herbal medicine of Chinese medicine composition preparation
Liquid；
Specific Chinese medicine composition includes following raw material by weight:
160-480 parts of pueraria lobata, 80-320 parts of Radix Salviae Miltiorrhizae, 120-400 parts of Radix Paeoniae Alba, 120-400 parts of Radix Astragali, 40-240 parts of turmeric, Rhizoma Atractylodis Macrocephalae
60-280 parts, 40-240 parts of semen brassicae, 60-280 parts of hawthorn, 60-280 parts of radix bupleuri, 60-280 parts of chrysanthemum, 40-240 parts of Rhizoma Gastrodiae,
60-280 parts of panax japonicus, 60-280 parts of rhizoma cyperi, 40-240 parts of salvia chinensis；
When preparing decocting for Chinese herbal medicine liquid, Chinese medicine material will be weighed according to the ratio, and 8-10 times of raw material gross weight of water, first intense fire heating is added
It is cooked by slow fire 30-60min again to boiling, decocts to 4-5 times of water, slag filtration obtains the decocting for Chinese herbal medicine of the Chinese medicine composition
Liquid；
When specific preparation fermentation medical fluid, after taking saccharomycete, acetobacter and Bacillus acidi lactici according to the ratio, decocting for Chinese herbal medicine liquid is added,
It ferments 10-20 days, filters at 22-37 DEG C, fermentation medical fluid finished product can be obtained in disinfection.
2. the fermentation medical fluid of Chinese medicine composition according to claim 1, it is characterised in that: 320 parts of pueraria lobata, 160 parts of Radix Salviae Miltiorrhizae, white
240 parts of Chinese herbaceous peony, 240 parts of Radix Astragali, 80 parts of turmeric, 120 parts of Rhizoma Atractylodis Macrocephalae, 80 parts of semen brassicae, 120 parts of hawthorn, 120 parts of radix bupleuri, chrysanthemum 120
Part, 80 parts of Rhizoma Gastrodiae, 120 parts of panax japonicus, 120 parts of rhizoma cyperi, 80 parts of salvia chinensis.
3. the fermentation medical fluid of Chinese medicine composition according to claim 1, it is characterised in that: when preparing decocting for Chinese herbal medicine liquid, add water
Chinese medicine material afterwards first impregnates 20-60min, then carries out heating decoction.
4. the fermentation medical fluid of Chinese medicine composition according to claim 1, it is characterised in that: by weight: every 10000 parts
Contain 10 parts of saccharomycete, 10 parts of acetobacter, 10 parts of Bacillus acidi lactici in fermentation medical fluid, remaining is the Chinese medicine of Chinese medicine composition preparation
Decoction liquor.
5. the fermentation medical fluid of Chinese medicine composition described in claim 1-4 any one treats ischemic cerebral disease drug side in preparation
The application in face.
6. the fermentation medical fluid of Chinese medicine composition described in claim 1-4 any one is treated intravascular caused by oxidative stress in preparation
Application in terms of endothelial apoptosis drug.
7. the fermentation medical fluid of Chinese medicine composition described in claim 1-4 any one treats vascular dementia, headache, head in preparation
Application dizzy, in terms of tinnitus drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610302578.1A CN105833184B (en) | 2016-05-09 | 2016-05-09 | A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610302578.1A CN105833184B (en) | 2016-05-09 | 2016-05-09 | A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105833184A CN105833184A (en) | 2016-08-10 |
| CN105833184B true CN105833184B (en) | 2019-07-26 |
Family
ID=56591606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610302578.1A Expired - Fee Related CN105833184B (en) | 2016-05-09 | 2016-05-09 | A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105833184B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106667905A (en) * | 2017-03-20 | 2017-05-17 | 河南省长义农业科技有限公司 | Method for producing complete plant enzyme/traditional Chinese medicine oral liquid |
| CN107823458A (en) * | 2017-11-29 | 2018-03-23 | 徐小毛 | It is a kind of to be used to treat apoplexy and the Chinese medicine of apoplexy complication and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087275A (en) * | 1992-11-28 | 1994-06-01 | 中国人民解放军第371医院 | Treatment ischemic brain, cardiovascular preparation Shumaining |
| CN1437959A (en) * | 2002-02-10 | 2003-08-27 | 杨志东 | Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method |
| CN1872329A (en) * | 2005-06-03 | 2006-12-06 | 天津天士力制药股份有限公司 | Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain |
| CN101314002A (en) * | 2008-07-21 | 2008-12-03 | 秦周顺 | Medicament for treating blood supply insufficiency of brain |
| CN101780223A (en) * | 2010-04-09 | 2010-07-21 | 任添华 | Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease |
| CN102727819A (en) * | 2012-07-05 | 2012-10-17 | 陈光明 | Baokangling multi-element probiotics oral liquid for treating digestive system disease and preparation method thereof |
| CN103736037A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Medicine for treating chronic fatigue syndrome and preparation method thereof |
| CN104013831A (en) * | 2014-06-05 | 2014-09-03 | 黄艳梅 | Medicament for treating insufficient blood supply |
-
2016
- 2016-05-09 CN CN201610302578.1A patent/CN105833184B/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087275A (en) * | 1992-11-28 | 1994-06-01 | 中国人民解放军第371医院 | Treatment ischemic brain, cardiovascular preparation Shumaining |
| CN1437959A (en) * | 2002-02-10 | 2003-08-27 | 杨志东 | Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method |
| CN1872329A (en) * | 2005-06-03 | 2006-12-06 | 天津天士力制药股份有限公司 | Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain |
| CN101314002A (en) * | 2008-07-21 | 2008-12-03 | 秦周顺 | Medicament for treating blood supply insufficiency of brain |
| CN101780223A (en) * | 2010-04-09 | 2010-07-21 | 任添华 | Traditional Chinese medicine with integral coordination function for treating ischemic cerebrovascular disease |
| CN102727819A (en) * | 2012-07-05 | 2012-10-17 | 陈光明 | Baokangling multi-element probiotics oral liquid for treating digestive system disease and preparation method thereof |
| CN103736037A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Medicine for treating chronic fatigue syndrome and preparation method thereof |
| CN104013831A (en) * | 2014-06-05 | 2014-09-03 | 黄艳梅 | Medicament for treating insufficient blood supply |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105833184A (en) | 2016-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101433654B (en) | Chinese medicine preparation for treating women's chronic pelvic inflammatory disease and preparation method thereof | |
| CN102000164B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN103749824B (en) | A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof | |
| CN103211930A (en) | Traditional Chinese preparation for reducing blood fat and blood pressure | |
| CN105833184B (en) | A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application | |
| CN101347584A (en) | Medicament for treating primary hypertension and preparation method thereof | |
| CN1330367C (en) | Chinese medicine composition for treating premenstrual stage stress syndrome an dits prepn process | |
| CN107349284A (en) | A kind of medicine for treating blood stasis type apoplexy | |
| CN115252691B (en) | Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina | |
| CN103071082A (en) | Traditional Chinese medicine composition for treating chronic nephritis | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN103041119B (en) | One treats cardiopathic Chinese medicine | |
| CN115212284A (en) | Chinese medicinal compound for treating ischemic stroke and preparation method thereof | |
| CN102614462A (en) | Traditional Chinese medicine composition for curing coronary disease and preparation method thereof | |
| CN103202938B (en) | Traditional Chinese medicine decoction for treating enteritis | |
| CN100551427C (en) | A kind of Chinese medicinal capsule for the treatment of hyperlipidemia | |
| CN103285328A (en) | Traditional Chinese medicine composition capsule for treating coronary heart diseases and preparation method thereof | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof | |
| CN103330911B (en) | Chinese medicine powder for treating coronary heart disease and preparation method thereof | |
| CN103285327B (en) | Traditional Chinese medicine composition tablet for treating coronary heart diseases and preparation method thereof | |
| CN104840774A (en) | Traditional Chinese medicine for treating liver and kidney yin deficiency and liver yang hyperactivity type hypertension | |
| CN100388929C (en) | Medicine for treating hyperlipidemia | |
| CN104906506A (en) | Traditional Chinese medicine composition for treating blood stasis and qi stagnation type amenorrhea and preparation method thereof | |
| CN103751712A (en) | Preparation method of traditional Chinese medicine for treating heart-blood-stagnation-type hyperlipemia | |
| CN103751677A (en) | Preparation method of traditional Chinese medicine for treating qi/blood-deficiency-type hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210511 Address after: Room 703-1 and 703-2, 7 / F, Qinzhou hi tech Industry Service Center (incubation complex building), 9 Longxiang Road, Qinzhou City, Guangxi Zhuang Autonomous Region, 535000 Patentee after: Guangxi chuse Biotechnology Co.,Ltd. Address before: No.716, 7th floor, building 4, No.99 Guangfu Road, Wuhou District, Chengdu, Sichuan 610000 Patentee before: Chengdu yishenrui Technology Co.,Ltd. Effective date of registration: 20210511 Address after: No.716, 7th floor, building 4, No.99 Guangfu Road, Wuhou District, Chengdu, Sichuan 610000 Patentee after: Chengdu yishenrui Technology Co.,Ltd. Address before: 443002 No. 8, University Road, Yichang, Hubei Patentee before: CHINA THREE GORGES University |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190726 |